Cancer drug developer Heat Biologics adds shares to IPO

Hoping to capture some of the new excitement for select biotech IPOs, Heat Biologics bumped the size of the maiden offering today to 2.3 million shares. At the top of its $10 to $12 range, the offering could raise more than $27 million. The Chapel Hill, NC-based cancer and infectious disease drug developer was founded 5 years ago, develops new immunotherapies and will trade as HTBX. This will be the 23rd biotech IPO of the year. Story

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.